HK$5.32
0.76%
Hong Kong, Sep 17, 03:49 pm HKT. Closed.
ISIN
KYG674111011
Symbol
1477

Ocumension Therapeutics Target price 2026 - Analyst rating & recommendation

Ocumension Therapeutics Classifications & Recommendation

Buy
75%
Hold
25%

Ocumension Therapeutics Price Target

Target Price HK$8.36
Price HK$5.35
Potential
Number of Estimates 4
4 Analysts have issued a price target Ocumension Therapeutics 2027 . The average Ocumension Therapeutics target price is HK$8.36. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 6 Analysts recommend Ocumension Therapeutics to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ocumension Therapeutics stock has an average upside potential 2027 of . Most analysts recommend the Ocumension Therapeutics stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Million HK$ 940.84 1,294.84
92.75% 37.63%
EBITDA Margin -19.15% 10.50%
71.32% 154.82%
Net Margin -19.75% 3.01%
69.29% 115.24%

4 Analysts have issued a sales forecast Ocumension Therapeutics 2026 . The average Ocumension Therapeutics sales estimate is

HK$1.3b
unlock
. This is
37.63% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$1.4b 44.22%
unlock
, the lowest is
HK$1.2b 29.92%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$941m 92.75%
2026
HK$1.3b 37.63%
unlock
2027
HK$1.7b 28.46%
unlock
2028
HK$2.4b 43.39%
unlock
2029
HK$3.2b 34.18%
unlock
2030
HK$3.8b 19.26%
unlock
2031
HK$4.4b 15.32%
unlock
2032
HK$5.0b 12.94%
unlock
2033
HK$5.4b 8.82%
unlock

4 Analysts have issued an Ocumension Therapeutics EBITDA forecast 2026. The average Ocumension Therapeutics EBITDA estimate is

HK$136m
unlock
. This is
175.46% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HK$171m 194.71%
unlock
, the lowest is
HK$102m 156.61%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 HK$-180m 44.71%
2026
HK$136m 175.46%
unlock
2027
HK$203m 49.03%
unlock
2028
HK$546m 169.23%
unlock

EBITDA Margin

2025 -19.15% 71.32%
2026
10.50% 154.82%
unlock
2027
12.18% 16.00%
unlock
2028
22.88% 87.85%
unlock

4 Ocumension Therapeutics Analysts have issued a net profit forecast 2026. The average Ocumension Therapeutics net profit estimate is

HK$38.9m
unlock
. This is
120.95% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$70.1m 137.73%
unlock
, the lowest is
HK$9.4m 105.03%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$-186m 40.80%
2026
HK$38.9m 120.95%
unlock
2027
HK$141m 262.53%
unlock
2028
HK$418m 196.55%
unlock

Net Margin

2025 -19.75% 69.29%
2026
3.01% 115.24%
unlock
2027
8.48% 181.73%
unlock
2028
17.54% 106.84%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ -0.23 0.05
50.00% 121.74%
P/E 110.64
EV/Sales 3.04

4 Analysts have issued a Ocumension Therapeutics forecast for earnings per share. The average Ocumension Therapeutics EPS is

HK$0.05
unlock
. This is
120.83% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$0.09 137.50%
unlock
, the lowest is
HK$0.01 104.17%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$-0.23 50.00%
2026
HK$0.05 121.74%
unlock
2027
HK$0.17 240.00%
unlock
2028
HK$0.51 200.00%
unlock

P/E ratio

Current -22.00 15.13%
2026
110.64 602.91%
unlock
2027
30.52 72.42%
unlock
2028
10.29 66.28%
unlock

Based on analysts' sales estimates for 2026, the Ocumension Therapeutics stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.18
2026
3.04 27.33%
unlock
2027
2.36 22.15%
unlock
2028
1.65 30.26%
unlock
2029
1.23 25.47%
unlock
2030
1.03 16.15%
unlock
2031
0.89 13.28%
unlock
2032
0.79 11.46%
unlock
2033
0.73 8.11%
unlock

P/S ratio

Current
2026
3.36 27.34%
unlock
2027
2.62 22.15%
unlock
2028
1.83 30.26%
unlock
2029
1.36 25.47%
unlock
2030
1.14 16.15%
unlock
2031
0.99 13.29%
unlock
2032
0.88 11.45%
unlock
2033
0.80 8.11%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today